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The Wilms’ tumor suppressor gene, WT1, encodes a zinc
ﬁnger protein that regulates podocyte development and is
highly expressed in mature podocytes. Mutations in the
WT1 gene are associated with the development of renal
failure due to the formation of scar tissue within glomeruli,
the mechanisms of which are poorly understood. Here, we
used a tamoxifen-based CRE-LoxP system to induce
deletion of Wt1 in adult mice to investigate the
mechanisms underlying evolution of glomerulosclerosis.
Podocyte apoptosis was evident as early as the fourth day
post-induction and increased during disease progression,
supporting a role for Wt1 in mature podocyte survival.
Podocyte Notch activation was evident at disease onset
with upregulation of Notch1 and its transcriptional targets,
including Nrarp. There was repression of podocyte FoxC2
and upregulation of Hey2 supporting a role for a Wt1/
FoxC2/Notch transcriptional network in mature podocyte
injury. The expression of cleaved Notch1 and HES1 proteins
in podocytes of mutant mice was conﬁrmed in early
disease. Furthermore, induction of podocyte HES1
expression was associated with upregulation of genes
implicated in epithelial mesenchymal transition, thereby
suggesting that HES1 mediates podocyte EMT. Lastly, early
pharmacological inhibition of Notch signaling ameliorated
glomerular scarring and albuminuria. Thus, loss of Wt1 in
mature podocytes modulates podocyte Notch activation,
which could mediate early events in WT1-related
glomerulosclerosis.
Kidney International (2018) -, -–-; https://doi.org/10.1016/
j.kint.2017.11.014
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G lomerulosclerosis accounts for 5% to 10% of pediatricand adult end-stage kidney disease and recurs in 15%to 30% of patients following kidney transplantation.1
Mutations in genes encoding transcription factors which
regulate podocyte differentiation have been implicated in hu-
man glomerulosclerosis and include Wilms’ tumor 1
(WT1).2–7 WT1 encodes a nuclear protein containing 4 zinc
ﬁngers that bind DNA and RNA and is highly expressed in
mature podocytes.8–11 Mutations in the regions involved in
DNA binding or zinc ﬁnger formation have been reported
in patients with Denys-Drash syndrome, a disorder associated
with infantile diffuse mesangial sclerosis, gonadal dysgenesis,
and Wilms’ tumor.12–14 Mutations disrupting an alternative
splice donor site in intron 9, results in Frasier syndrome, a
disorder associated with focal segmental glomerulosclerosis
(FSGS), predisposition to gonadoblastoma, and male pseudo-
hermaphroditism.15,16 Furthermore, mutations in WT1 have
been reported in isolated primary steroid-resistant nephrotic
syndrome, supporting a role for aberrant Wt1 function in
the pathogenesis of glomerulosclerosis.5,7
Mechanisms underlying the development of WT1-related
glomerulosclerosis are poorly understood with no effective
treatments available. Recent studies employing chromatin
immunoprecipitation sequencing, RNA sequencing, exon
array, and bioinformatic analyses have shown a speciﬁc role
for WT1 in regulating the podocyte-speciﬁc transcriptome.
WT1 can bind to both promoters and enhancers of
18 known podocytopathy genes.17,18 Mutations in WT1
could lead to altered transcriptional regulation of these
genes, which is necessary for podocyte differentiation
and function, and contribute to the pathogenesis of
glomerulosclerosis.17,18
Genes regulating podocyte differentiation have also been
implicated in the pathogenesis ofWT1-related disease.De novo
expression of PAX2 protein and mRNA, a paired box tran-
scription factor repressed by WT1 during nephrogenesis, has
been observed in podocytes of Denys-Drash syndrome patient
biopsies.19 Furthermore, re-expression of Pax2 in podocytes,
cell cycle re-entry, and reduced expression of podocyte proteins
such as nephrin and a-actinin-4 have been reported in het-
erozygous Wt1tmT396/þ mice with glomerulosclerosis by 8
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months of age.20 These ﬁndings suggested that Wt1tmT396/þ
podocytes dedifferentiate and revert to an immature phenotype
during disease progression.20
During glomerulogenesis, podocyte fate induction is regu-
lated byNotch, a highly conserved and ubiquitous pathway that
transduces short-range signals between neighboring cells.21–24
Ligand binding initiates regulated intramembrane proteolysis
with subsequent nuclear translocation of the Notch intracel-
lular domain (NICD) where it associates with RBPJ-k, a DNA-
binding protein, and promotes transcription of target genes
(e.g., hairy enhancer of split [Hes]), which regulates tissue-
speciﬁc differentiation. Notch1, Notch2, and downstream
transcriptional targetsHes1 andHey1 are expressed in podocyte
precursors in the S-shaped body and are down-regulated
during terminal differentiation.25,26 Ectopic podocyte Notch
activation in differentiating andmature podocytes is associated
with both diffuse mesangial sclerosis and FSGS, respectively,
the latter being mediated by p53-induced podocyte apoptosis
and the former associated with de novo Pax2 expression.27,28
Given the interplay between WT1 and Notch during glomer-
ulogenesis and the fact that both diffusemesangial sclerosis and
FSGS phenotypes occur with mutations in WT1 as well as
ectopic podocyte Notch activation, we hypothesized a role for
podocyte Notch activation in the development of glomerulo-
sclerosis related to loss of Wt1 function.
In a model where Wt1 was deleted in mature podocytes,
using a tamoxifen-based CRE-LoxP system, we observed
increased podocyte loss during the development of glomer-
ulosclerosis. At disease onset, we found upregulation of Notch
pathway transcripts in mutant podocytes. At the same time
point, we observed repression of FoxC2 and upregulation of
Hey2 transcripts in primary mutant podocytes. Cleaved
Notch1 and HES1 proteins were evident in mutant podocytes
at disease manifestation. Induction of podocyte HES1 expres-
sion in vitro was associated with increased expression of Slug
and Snail transcripts, genes implicated in epithelial to mesen-
chyme transition. Pharmacological inhibition of Notch with
gamma-secretase inhibitors at disease onset rescued the
severity of glomerulosclerosis and albuminuria. These data
support a role for early Notch activation in themanifestation of
Wt1 glomerulopathy, which may be mediated via repression of
podocyte FoxC2.
RESULTS
Early glomerulosclerosis is evident at 5 days post tamoxifen
induction in CAGG-CreERTMþ/;Wt1f/f transgenic mice
Wt1 deletion in mature podocytes results in glomerulosclerosis
with compromised renal function by day 7 post tamoxifen
induction in adult CAGG-CreERTMþ/;Wt1f/f transgenic
mice.29 To investigate events leading to the induction of disease
in thesemice, we ﬁrst determined the earliest point at whichwe
could detect glomerulosclerosis after Wt1 deletion. Tamoxifen
was administered for 3 consecutive days by i.p. injection to
5-week-old CAGG-CreERTMþ/;Wt1f/f transgenic mice and
mice were nephrectomized at 4, 5, 6, and 12 days following
injection. Successful Wt1 deletion was demonstrated by
recombination polymerase chain reaction (PCR) and the
reduction of Wt1 expression in glomeruli (Supplementary
Figure S1). Following light microscopy analysis of periodic
acid–Schiff (PAS)-stained kidney sections, we determined the
severity of glomerulosclerosis by a semiquantitative analysis at
each time point in CAGG-CreERTMþ/;Wt1f/fmutants, CAGG-
CreERTM/;Wt1f/f controls, and heterozygous CAGG-
CreERTMþ/;Wt1f/þ mice (Figure 1a–d).
Heterozygous mice did not develop glomerulosclerosis by
day (D) 12 postinduction (PI) (Supplementary Figure S2). At
D4 PI, mutants exhibited early segmental glomerulosclerosis
with focal foot process effacement and a trend toward higher
levels of albuminuria (P ¼ 0.21) (Figure 1a and a0;
Supplementary Figures S3A and S4). By D5 PI, glomerular
scarring was more extensive ($ score 2) in mutants compared
with control and heterozygous mice (*P < 0.05) (Figure 1b,
Supplementary Figure S3B). Progression of disease was
further supported by an increase in urine albumin-creatinine
ratio in mutants compared with controls (*P ¼ 0.01)
(Figure 1b0). By D6 PI, extensive glomerulosclerosis with
tubules containing protein casts were observed in mutants
relative to controls with increased albuminuria (Figure 1c and
c0, Supplementary Figure S3C). Late stage disease with global
glomerulosclerosis was observed at D12 PI (Figure 1d and e,
Supplementary Figure S3D), with peritubular cells expressing
vascular smooth muscle actin, consistent with progression of
tubulointerstitial disease (Supplementary Figure S5). We
conclude that podocyte function appears compromised
within 6 days ofWt1 deletion in mature podocytes. Therefore,
investigations into the mechanisms underlying manifestation
of disease should be undertaken within this time frame.
Cleaved-Caspase-3 protein expression increases in glomeruli
and podocytes of mutant mice at D5, D6, and D12 PI
Podocyte apoptosis has previously been implicated in the
pathogenesis of glomerulosclerosis.30 Therefore, we next
investigated whether apoptosis is evident during disease
induction in CAGG-CreERTMþ/;Wt1f/f transgenic mice.
Expression of Cleaved Caspase-3 protein was observed within
mutant glomeruli as early as D4 PI but quantitatively, was not
statistically signiﬁcantly different compared with control
glomeruli (Figure 2a) (P ¼ 0.06, NS). By D5 PI, at the
onset of early glomerulosclerosis, we observed an increased
number of Cleaved Caspase-3/DAPI-positive cells in
mutant glomeruli (Figure 2c, c0, and d) (***P < 0.0001),
consistent with a temporal increase in apoptosis. Terminal
deoxynucleotidyltransferase–mediated 20-deoxyuridine 50-
triphosphate nick end-labeling (TUNEL)-positive mutant
glomerular cells were evident at D5 PI but were absent in
controls (Supplementary Figure S6). TUNEL staining of D6
PI primary mutant podocytes was also higher than for con-
trols (Figure 2e, e0, and f) (*P ¼ 0.04). At the same time
point, we observed increased Caspase-3/7 positivity in pri-
mary mutant podocytes (Supplementary Figure S7) and an
increased number of Annexin V/Sytox blue-positive primary
mutant podocytes compared with controls (Supplementary
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Figure S8). TUNEL staining at D12 PI revealed clusters of
TUNEL-positive cells in peripheral segments of mutant
glomeruli not evident in the glomeruli of controls
(Supplementary Figure S9). Together, these studies suggest
that loss of Wt1 in mature podocytes is associated with
podocyte apoptosis and development of glomerulosclerosis.
Podocyte Notch activation precedes glomerulosclerosis in
CAGG-CreERTMþ/;Wt1f/f transgenic mice
Constitutive Notch activation in terminally differentiated podo-
cytes results in podocyte apoptosis and glomerulosclerosis,27,28
supporting a role for Notch in podocyte injury. Following
our observation of increased podocyte apoptosis in CAGG-
CreERTMþ/;Wt1f/f transgenic mice, we hypothesized that
podocyte Notch activation plays a role in early Wt1 glo-
merulopathy. At D4 PI before manifestation of disease,
Notch pathway transcripts in primary podocytes of CAGG-
CreERTMþ/;Wt1f/f transgenic mice were not statistically
different to those of controls (Supplementary Figure S10).
By D6 PI, concomitant with early glomerulosclerosis and
albuminuria, we observed increases in canonical Notch
pathway transcripts, Notch1, Nrarp, and Hey2. Increased
Figure 1 | Temporal induction of glomerulosclerosis in CAGG-CreERTM/þ;Wt1f/f transgenic mice following tamoxifen induction (a–d). (a)
At day (D) 4 postinduction (PI), glomeruli of CAGG-CreERTM/þ;Wt1f/f transgenic mice (mutants) are morphologically similar to their controls,
CAGG-CreERTM/;Wt1f/f transgenic mice. (See Supplementary Figure S2 for analysis of heterozygous CAGG-CreERTM/þ;Wt1f/þ littermates and
Supplementary Figure S3 for analysis of severity of glomerulosclerosis). Bars ¼ 50 mm. (a0) Quantitative graph showing mean urine albumin-
creatinine ratio (mg/mg) SEM at D4 PI controls versus mutants (n ¼ 14 vs. n ¼ 10); 104.4  25.71 versus 563.5  443, P ¼ 0.21, Student t-test.
(b) At D5 PI, mutant mice exhibit segmental glomerulosclerosis compared with control mice (for quantitative analysis, see also Supplementary
Figure S3). (b0) Quantitative graph showing mean urine albumin-creatinine ratio (mg/mg) at D5 PI in controls versus mutants (n ¼ 14 vs. n ¼ 14);
217  157.5 versus 11,654  4304, *P ¼ 0.01, Student t-test. (c) At D6 PI, more extensive glomerulosclerosis is evident in mutants compared
with control mice with hyaline-ﬁlled tubules. (c0) Quantitative graph showing mean urine albumin-creatinine ratio (mg/mg) at D6 PI in controls
versus mutants (n ¼ 5 vs. n ¼ 6); 79.8  29.8 versus 15,202  7210, **P ¼ 0.004, Student t-test. (d) By D12 PI, glomeruli of mutant mice exhibit
global glomerulosclerosis, hyaline-ﬁlled tubules, and pyknotic podocyte nuclei with extensive tubulointerstitial disease (see also Supplementary
Figure S5). (d0) Quantitative graph showing mean urine albumin-creatinine ratio (mg/mg) at D12 PI controls versus mutants (n ¼ 7 vs. n ¼ 7);
76.8  13.9 versus 9469  4279, *P ¼ 0.04, Student t-test. (e) Western blot analysis from D4, D5, D6, and D12 PI shows evidence of increased
albuminuria in mutant urine during disease progression in CAGG-CreERTM/þ;Wt1f/f transgenic mice compared with Cre-negative control mice.
To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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levels of other Notch basic helix loop helix (bHLH) tran-
scription factors Hes1, Hes3, Hes5, and HeyL were also
observed in primary mutant podocytes but not in controls
(Figure 3a), although these changes did not reach statistical
signiﬁcance. Using double immunoﬂuorescence labeling, we
observed cleaved Notch1 protein in nuclei of Nestin-positive
podocytes as early as D4 PI in mutant kidney sections
(Figure 3b and c). These ﬁndings were validated by Western
blot analysis showing increased cleaved Notch1 protein in
primary mutant podocytes relative to controls (Figure 3d).
Increased podocyte Manic fringe (MFng) transcript was also
observed in mutants compared with controls (Figure 3a).
Manic Fringe is a glycosyltransferase that mediates glyco-
sylation of the extracellular domain of Notch receptors
Figure 2 | Podocyte apoptosis in CAGG-CreERTM/þ;Wt1f/f transgenic mice following tamoxifen administration (a,a0). Shown are split-
channel and merged micrographs of glomeruli following double immunoﬂuorescence labeling of transgenic mouse kidney tissue sections
with anti-Cleaved-Caspase-3 (Casp-3) (Alexa Fluor 594–conjugated secondary antibody) and anti-Podoplanin (Alexa Fluor 488–conjugated
secondary antibody) at day (D) 4 postinduction (PI). Images were counterstained with 40,6-diamidino-2-phenylindole (DAPI). At D4 PI,
Cleaved-Caspase-3–positive, Podoplanin-positive cells were observed in DAPI-positive cells in mutant glomeruli (a0) and not in control
glomeruli (a0). Bars ¼ 25 mm. (b) Quantitative graphs showing mean percentage of DAPI-positive, Cleaved-Caspase-3–positive cells per
glomerulus at D4 PI in control and mutant mice. Bars represent mean and error bars indicate the SEM. A nonsigniﬁcant increase was
observed in the number of DAPI-positive, Cleaved-Caspase-3–positive glomerular cells in control versus mutant mice at D4 PI: controls
versus mutants (n ¼ 79 vs. n ¼ 80 glomeruli from n ¼ 3 per genotype); 1.6  0.3% versus 3.0  0.4%, P ¼ 0.06, not signiﬁcant (NS). Student
t-test. (c,c0) At D5 PI, Cleaved-Caspase-3–positive (red arrows), DAPI-positive cells in mutant glomeruli stained with Podoplanin (inset, white
arrows) and not in control glomeruli. (d) Quantitative graphs showing mean percentage of DAPI-positive, Cleaved-Caspase-3–positive,
Podoplanin-positive cells per glomerulus at D5 PI in control and mutant mice: controls versus mutants (n ¼ 98 vs. n ¼ 107 glomeruli from
n ¼ 3 per genotype); 0.8  0.2% versus 3.6  0.4%, ***P < 0.0001, Student t-test. (e,e0) Representative micrographs following immuno-
ﬂuorescent labeling of terminal deoxynucleotidyltransferase–mediated 20-deoxyuridine 50-triphosphate nick end-labeling (TUNEL)–positive
primary podocytes (Alexa Fluor 488–conjugated secondary antibody, green arrows) isolated at D6 PI from control and mutant mice.
Sections were counterstained with DAPI. (e0 0) Higher-power magniﬁcation showing a cell nucleus–expressing TUNEL-positive signal. (f)
Quantitative graph of apoptotic cells calculating proportion of TUNEL-DAPI–positive podocytes at D6 posttamoxifen in vitro. Bars represent
the mean, and error bars represent the SEM. CAGG-CreER/;Wt1f/f (n ¼ 2 samples, 10 ﬁelds quantiﬁed per sample) versus CAGG-CreERþ/;
Wt1f/f (n ¼ 2 mice per genotype, 10 ﬁelds quantiﬁed per primary podocyte line per mouse); 1.4  0.2% versus 6.3  1.0%, *P ¼ 0.04, Student
t-test. See also Supplementary Figure S6 for primary podocyte caspase-3/7 staining; Supplementary Figure S7 for TUNEL staining in vivo at
D5 PI, and Supplementary Figure S8 for Annexin V PI staining of primary podocytes for control and mutant transgenic mice. To optimize
viewing of this image, please see the online version of this article at www.kidney-international.org.
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during signal transduction.31,32 We also found upregulation
of Pofut1 protein in primary mutant podocytes at D6 PI
(Figure 3e). Pofut1 is an O-fucosyltransferase 1 enzyme that
mediates fucosylation of the extracellular domain of the
Notch.33 Together, these data suggest that post-translational
modiﬁcation of Notch components are active in early Wt1
glomerulopathy.
We next sought to determine whether the Notch
ligand Jagged1 is expressed in CAGG-CreERTMþ/;Wt1 f/f
transgenic mice owing to previous studies implicating
podocyte Jagged1 in glomerulosclerosis.28 We observed a
striking upregulation of Jagged1 protein in the parietal
epithelium of mutants compared with controls (Figure 4a
and b). Within segments of mutant glomeruli, foci of
Figure 3 | Notch activation coincides with onset of glomerulosclerosis in in CAGG-CreERTM/þ;Wt1f/f transgenic mice following
tamoxifen administration. (a) Relative mean transcript levels of Notch pathway components in primary podocytes of mutants compared with
controls at day (D) 6 post-induction (PI). Bars represent means and error bars represent SDs. CAGG-CreERTM/;Wt1f/f (n ¼ 6) versus CAGG-
CreERTMþ/;Wt1f/f (n ¼ 10): mean Notch1, 1.1  0.2 versus 2.5  0.5, *P ¼ 0.05; mean Nrarp, 0.9  0.4 versus 3.6  0.4, **P ¼ 0.001; mean Rbpsuh,
1.0  0.1 versus 1.7  0.3, P ¼ 0.09; mean Hes1, 1.0  0.1 versus 1.6  0.2, P ¼ 0.09; mean Hes3, 1.3  0.4 versus 2.1  0.5, P ¼ 0.25; mean Hes5,
1.0  0.2 versus 3.9  1.1, P ¼ 0.07; mean Hey1, 1.1  0.3 versus 2.2  0.4, P ¼ 0.11; mean Hey2, 1.2  0.3 versus 4.0  1, *P ¼ 0.04; mean HeyL,
1.1  0.2 versus 2.3  0.5, P ¼ 0.14; mean MFng, 1.9  0.9 versus 5.0  2.4, P ¼ 0.19; mean FoxC2, 1.2  0.4 versus 0.3  0.2, *P ¼ 0.04, Student
t-test. (b) Shown are representative images of glomeruli following double immunoﬂuorescence labeling of D6 PI mouse kidney sections with
anticleaved Notch1 (Val1744) and anti-Nestin of CAGG-CreERTM/;Wt1f/f (controls) and CAGG-CreERTMþ/;Wt1f/f (mutants) transgenic mice
following multichannel labeling with Alexa Fluor 488–conjugated secondary antibody (Nestin, demarcates podocytes) and Alexa Fluor 594–
conjugated secondary antibody (cleaved Notch1). Sections are counterstained with DAPI. Arrows show positive cleaved Notch1 nuclear staining
in mutant glomeruli within Nestin-positive cells that are not evident in control glomeruli. Bars ¼ 50 mm. Inset shows high-power view of same
cells. Bar ¼ 10 mm. (c,d) Representative images of Western blot analyses of protein derived from primary podocytes isolated from mutants and
control mice. Immunoblots show that cleaved Notch1 (Val1744) (c) and Pofut1 (d) are expressed at D6 PI in mutant podocytes but not in
controls. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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Podocin-positive cells expressing Jagged1 were also observed
(Figure 4b0, high-power images). Immunoblotting of pri-
mary mutant and control podocyte lysates revealed induc-
tion of Jagged1 expression at D6 PI (Figure 4c). Together,
these data suggest that Notch signaling is activated when
glomerulosclerosis ﬁrst manifests following deletion of Wt1
in mature podocytes.
Given previous studies that showed that Wt1 and Foxc1a
can inhibit NICD activation,34 we explored FoxC2 expression
in this model. Using semiquantitative PCR analysis, we
found decreased podocyte FoxC2 transcript in CAGG-
CreERTMþ/;Wt1 f/f transgenic mice compared with their
control littermates (*P ¼ 0.04) (Figure 3a). This decrease was
observed at the same time point when Notch components
were upregulated and concordant with disease manifestation.
These ﬁndings support the hypothesis that Notch activation
in mature podocytes is normally repressed by FoxC2 and
WT1 and loss of these proteins is associated with increased
podocyte Notch activation.
Podocyte HES1 expression is evident at onset of
glomerulosclerosis and is associated with podocyte epithelial
to mesenchyme gene expression
Following detection of podocyte Hes/Hey mRNA expression
in primary mutant podocytes, we sought to validate the
expression of HES1, a bHLH transcription factor in podo-
cytes by triple immunoﬂuorescence labeling. We observed
clusters of HES1-expressing cells that were positive for the
podocyte marker, Synaptopodin, at onset of glomerulo-
sclerosis in mutants compared with controls (Figure 5).
HES1-positive glomerular epithelial cells were observed in
regions distinct from HES1-positive Lotus tetragonolobus
lectin (LTL)-positive tubules (Figure 5b and b0). Clusters of
Synaptopodin-positive HES1-podocytes were distinct from
platelet–endothelial cell adhesion molecule–positive glomer-
ular endothelial cells (Figure 5c, d, and d0). As HES1 has been
previously implicated in epithelial to mesenchymal transition
(EMT), we next determined that Snail and Slug transcript was
upregulated in primary D6 PI mutant podocytes compared
Figure 4 | Jagged 1 is expressed in glomeruli of CAGG-CreERTM/þ;Wt1f/f transgenic mice at day (D) 6 postinduction (PI). (a,b) Shown are
representative images of glomeruli following double immunoﬂuorescence labeling of D6 PI mouse kidney sections with anti-Jagged1 and anti-
Podocin of CAGG-CreERTM/;Wt1f/f (controls, a) and CAGG-CreERTMþ/;Wt1f/f (mutant, b) mice following multichannel labeling with Alexa Fluor
488–conjugated secondary antibody (Podocin, demarcates podocytes) and Alexa Fluor 594–conjugated secondary antibody (Jagged1). Sections
are counterstained with 40,6-diamidino-2-phenylindole (DAPI). Red arrows show positive Jagged1 staining in the parietal epithelium, areas of
podocyte adhesion (on the surface of Podocin-positive podocytes, green arrows, [b]; white arrows in merged image) to Bowman’s capsule
and in the glomerular stalk of mutant glomeruli that are not evident in control glomeruli. Bar ¼ 50 mm. (a0,b0) Higher-power views showing
perimembranous expression of Jagged1 (green) in Podocin-positive podocytes (red) in mutants (b0) compared to controls (a0).
(c) Representative images are shown of Western blot analyses of protein derived from primary podocytes isolated from mutants and control
mice. Immunoblots show that Jagged1 is increased at D6 PI in mutant podocytes but not in controls. To optimize viewing of this image,
please see the online version of this article at www.kidney-international.org.
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Figure 5 | Hairy enhancer of split 1 (HES1) expression coincides with onset of glomerulosclerosis in CAGG-CreERTMþ/;Wt1f/f transgenic
mice. (a,b,b0) Shown are representative images of glomeruli following double immunoﬂuorescence labeling of day (D) 5 postinduction (PI)
mouse kidney sections with anti-HES1, anti-Synaptopodin, and Lotus tetragonolobus lectin (LTL) of CAGG-CreERTM/;Wt1f/f (mutant) and CAGG-
CreERTMþ/;Wt1f/f (control) transgenic mice following multichannel labeling with Alexa Fluor 488–conjugated secondary antibody (LTL, de-
marcates tubules), Alexa Fluor 594–conjugated secondary antibody (Hes1), and Alexa Fluor 647–conjugated secondary (Synaptopodin, de-
marcates podocytes). Sections are counterstained with 40,6-diamidino-2-phenylindole (DAPI). Bars ¼ 50 mm. (b,b0) In mutants, HES1-positive,
Synaptopodin-positive glomerular epithelial cells were observed in regions distinct from LTL-positive tubules. Bars ¼ 50 mm. (b0) Bars ¼ 10 mm.
(c,d,d0) Segmental clusters of nuclear HES1 expression in Synaptopodin-positive, platelet–endothelial cell adhesion molecule (PECAM)-negative
podocytes are evident in mutant glomeruli and not evident in control glomeruli. Bars ¼ 50 mm. (e) Upregulation of podocyte Snail and Slug
transcript at onset of glomerulosclerosis at D6 PI. Median Snail mRNA expression at D6 PI in control versus mutant mice: 1.1 (interquartile range
[IQR]: 0.9, 1.2) versus 2.7 (IQR:1.8, 2.8), *P ¼ 0.045, Mann-Whitney test. Median Slug mRNA expression at D6 PI in control versus mutant mice: 1.2
(IQR: 0.6, 1.5) versus 2.8 (IQR: 1.4, 3.7), *P ¼ 0.03, Mann-Whitney test. (f) Increase in Hes1 mRNA in doxycycline-treated primary Nphs2;rtTA
podocytes transduced with TetOHes1 plasmid compared with untreated TetOHes1 and treated green ﬂuorescence protein (GFP)–transduced
primary Nphs2;rtTA podocytes. Mean Hes1 mRNA expression relative to Gapdh (SD): untreated control (GFP) versus untreated TetOHes1 versus
treated control (doxycycline 2 mg/ml) versus treated TetOHes1 (2 mg/ml) versus treated TetOHes1 (4 mg/ml): 1.15  0.66 versus 1.26  1.13
versus 1.21  0.88 versus 54.56  44.24 (**P < 0.004) versus 42.78  33.07 (**P < 0.008). No signiﬁcant difference in dose observed, P ¼ .045
(not signiﬁcant [NS]). (g) Upregulation of Snail and Slug transcripts, genes implicated in epithelial to mesenchyme transition in doxycycline-
treated primary Nphs2;rtTA podocytes transduced with TetOHes1 plasmid compared with untreated TetOHes1 and treated GFP-transduced
primary Nphs2;rtTA podocytes. Untreated control (GFP) versus untreated TetOHes1 versus treated TetOHes1 (4 mg/ml): mean Snail mRNA
expression relative to Gapdh (SD): 1.76  2.1 versus 1.01  0.31 versus 4.82  3.94, *P < 0.05. Mean Slug mRNA expression relative to Gapdh
(SD): 0.95  1.12 versus 0.31  0.26 versus 5.10  0.3.9 (*P < 0.05). To optimize viewing of this image, please see the online version of this
article at www.kidney-international.org.
RI Asfahani et al.: Podocyte Notch activation in Wt1 glomerulopathy ba s i c re sea r ch
Kidney International (2018) -, -–- 7
Figure 6 | JAGGED1 and hairy enhancer of split 1 (HES1) are expressed in Wilms’ tumor 1 (WT1) c.1390G>T mutant glomeruli. (a,b)
Shown are representative micrographs of glomeruli following double immunoﬂuorescence labeling of kidney sections from control (time-zero
renal allograft biopsy) and WT1 c.1390G>T mutant patient with anti-JAGGED1 (a) or anti-HES1 (b) antibodies (labeled with Alexa Fluor 594) and
anti-Nephrin antibody (demarcates podocyte slit diaphragm, and labeled with Alexa Fluor 488). (a) JAGGED1 is upregulated in parietal
epithelium of WT1 c.1390G>T mutant patient glomeruli compared with controls (red arrows) and is also expressed in a linear (continued)
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with controls (Figure 5e). To further understand the role of
HES1 in podocytes, we transfected cultured primary
Nphs2;rtTA transgenic murine podocytes with constructs
expressing either TetOHes1 or green ﬂuorescent protein
(GFP) alone. HES1 was not expressed in untreated TetOHes1
nor doxycycline-treated GFP transfected Nphs2;rtTA podo-
cytes. Treatment with doxycycline led to a dose-dependent
increase in podocyte Hes1 mRNA and protein expression
(Figure 5f, Supplementary Figure S11). Induction of Hes1
expression led to a 3-fold upregulation of Snail and Slug
transcript compared with untreated TetOHes1 transfected
and doxycycline-treated GFP transfected Nphs2;rtTA podo-
cytes (Figure 5f). These results suggest that podocyte HES1
induction could mediate manifestation of glomerulosclerosis
through regulation of EMT genes in podocytes.
Following our observation of Notch activation in murine
Wt1 glomerulopathy, we next tested biopsy samples from a
human subject with FSGS associated with the WT1
c.1390G>Tmutation. We found JAGGED1 expression in cells
with focal nephrin staining but also found that expression was
most marked in the parietal epithelium (Figure 6). The
control biopsy from a nondiseased time 0 renal allograft
biopsy revealed JAGGED1 expression in regions distal to
nephrin staining suggesting endothelial JAGGED1 expression.
JAGGED1 expression in the control parietal epithelium was
much less than in mutant WT1 patient tissue. Expression of
the Notch bHLH transcription factor, HES1, was also
observed in nuclei of mutant WT1 glomeruli compared with
in control biopsy tissue (Figure 6). We conclude that these
data support a role for Notch activation in human
WT1-mediated glomerular disease.
Gamma secretase inhibition of Notch ameliorates disease
severity in Wt1 glomerulopathy
As podocyte Notch activation is a feature of early disease, we
hypothesized that pharmacological Notch inhibition at onset of
glomerulosclerosis could inﬂuence severity of disease. CAGG-
CreERTMþ/;Wt1f/f transgenic mice were treated by i.p. injec-
tion with the gamma secretase inhibitor GSI-IX, N-[N-(3,
5-Diﬂuorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
(DAPT), or dimethylsulfoxide (i.e., vehicle only) late D4 PI and
early D5 PI (Figure 7a–d). In vehicle-treated mutants, we
observed hyaline-ﬁlled tubules representing proteinaceous
material and sclerotic glomeruli with mesangial proliferation
(Figure 7b). These features were not evident in GSI-IX-treated
mutants (Figure 7c). The proportion of vehicle-treated mutant
glomeruli exhibiting extensive glomerulosclerosis was signiﬁ-
cantly higher than the proportion of GSI-IX-treated mutants
(**P¼ 0.008) (Figure 7d). We validated inhibition of canonical
Notch pathway transcripts by semiquantitative PCR
(Figure 7e). Analysis of Wt1 transcript and protein expression
did not reveal a signiﬁcant difference between vehicle-treated
or GSI-IX-treated mutant mice (Supplementary Figure S12).
GSI-IX-treated mutants, compared with vehicle-treated mu-
tants, showed an improvement in urine albumin-creatinine
ratio at D5 PI (Figure 7f). Western blot analysis of urine al-
bumin conﬁrmed absence of albuminuria in GSI-IX-treated
mice compared with in vehicle-treated mutants at D5 PI
(Figure 7g). We conclude that the observed efﬁcacy of GSI
inhibition in amelioration of glomerulosclerosis supports the
hypothesis that Notch is activated during disease development.
We also tested the role of starting treatment in established
disease by administering GSI-IX to CAGG-CreER TMþ/;
Wt1f/f mutant mice on D7 PI. Following 2 doses of GSI-IX,
mice were nephrectomized late on D8 PI, and kidney
histology was analyzed for 2 mice per treatment. We did
not observe a difference in degree of glomerulosclerosis,
albuminuria, nor tubulointerstitial expression of vascular
smooth muscle actin immunoﬂuorescence (Supplementary
Figure S13). We hypothesize that podocyte Notch activation
plays a role in early Wt1 glomerulopathy.
Mfng and Rbpsuh short hairpin RNA knockdown does not
rescue podocyte EMT gene expression
Given the upregulation of MFng and Rbpsuh transcripts at D6
PI, we sought to determine whether knockdown of Mfng or
Rbpsuh would inﬂuence podocyte EMT gene or apoptosis
gene expression. While we did observe evidence of Mfng
and Rbpsuh down-regulation with repression of Hes1 and
Hes3 transcripts, we did not observe signiﬁcant repression of
podocyte Snail and Slug transcript nor signiﬁcant
upregulation of podocyte-speciﬁc transcripts such as Nphs1
nor Nphs2 (Supplementary Figure S14). Reduced primary
mutant podocyte viability precluded optimal transfection
owing to slow growth and increased apoptosis. We conclude
that genetic rescue of Wt1 glomerulopathy by Notch inhibi-
tion would be best validated with in vivo strategies.
DISCUSSION
Using an inducible model of Wt1 deletion, we demonstrate a
role for Notch activation in the pathogenesis of Wt1 glo-
merulopathy. The data provided in this study establish the
utility of temporal semiquantitative analysis of glomerular
scarring as a platform for the study of early pathological
events in an inducible model of mature podocyte injury. We
show that podocyte apoptosis is evident as early as the fourth
day following tamoxifen administration to adult CAGG-
CreERTMþ/;Wt1f/f transgenic mice before glomerulosclerosis
=
Figure 6 | (continued) pattern associated with focal nephrin staining in podocytes (white arrows). JAGGED1 expression is also expressed in the
endothelium of time-zero allograft glomeruli that do not exhibit glomerulosclerosis. Bars ¼ 50 mm. (b) HES1, the canonical Notch basic helix
loop helix transcription factor, is expressed basally in most cell types of both control and mutant glomerular tissue. Increased HES1 expression is
observed in nuclei of cells adjacent to Nephrin-positive podocytes of WT1 c.1390G>T mutant patient glomeruli with advanced glomerulo-
sclerosis. Bars ¼ 50 mm. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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is evident. This podocyte loss, secondary to Wt1 deletion,
increases when overt albuminuria is evident. Furthermore, we
show upregulation of Snail and Slug mRNA, genes that are
implicated in epithelial mesenchyme transition in primary
mutant podocytes coincident with onset of glomerulo-
sclerosis. Ectopic podocyte Notch activation in mice results in
Figure 7 | Gamma secretase inhibition of Notch ameliorates early Wilms’ tumor 1 (Wt1) glomerulopathy. (a–c) Shown are representative
micrographs of periodic acid–Schiff–stained sections of glomeruli of CAGG-CreERTM/;Wt1f/f (a), vehicle (dimethylsulfoxide)-treated CAGG-
CreERTMþ/–;Wt1f/f (b), and gamma secretase inhibitor (GSI-IX)-treated CAGG-CreERTMþ/;Wt1f/f transgenic mice (c) isolated late on day 5
postinduction. Bars ¼ 50 mm. (b) Vehicle-treated mice exhibit glomerulosclerosis with hyaline material in the tubules that was not seen in
control mice (a). Glomeruli of GSI-IX–treated mutants (c) do not show the same extent of glomerulosclerosis as vehicle-treated mutants. (d)
Quantitative graphs of a proportion of glomeruli per genotype revealing the extent of intraglomerulosclerosis (score 0: <25% glomerulus
sclerosed; score 1: 25%–50% sclerosis; score 2: 50%–75% sclerosis; score 3: >75% sclerosis). Bars represent the mean percentage of each score
per genotype. Error bars represent the SEMs. At day 5 postinduction, a higher proportion of GSI-IX–treated CAGG-CreERþ/;Wt1f/f transgenic
mice (n ¼ 52 glomeruli, n ¼ 5 mice) exhibited normal glomerular morphology compared with vehicle-treated CAGG-CreERþ/;Wt1f/f (mutants)
(n ¼ 52 glomeruli, n ¼ 4 mice): vehicle-treated CAGG-CreERþ/;Wt1f/f versus GSI-IX–treated CAGG-CreERþ/;Wt1f/f mutant transgenic mice: score
0: 18  0.9% versus 59  1.0%, *P < 0.02, Student t-test; score 2: 39  5% versus 8  3%, **P < 0.008, Student t-test. (e) Quantitative graph
showing reduced mean relative Rbpsuh, Hes1, Hes3, and Hes5 mRNA expression in podocytes from GSI-IX–treated and untreated mutant mice:
CAGG-CreERþ/;Wt1f/f versus GSI-IX–treated CAGG-CreERþ/;Wt1f/f mice: Rbpsuh: 1.2  0.2 versus 0.6  0.03, *P ¼ 0.01; Hes1: 1.1  0.1 versus 0.6
 0.01, P ¼ 0.05; Hes3: 1.4  0.3 versus 0.5  0.1, P ¼ 0.05; Hes5: 3.1  0.9 versus 2.0  0.4, P ¼ 0.1. Bars represent means and error bars
represent SEMs. (f) Quantitative graph showing median urine albumin-creatinine ratio in vehicle-treated versus GSI-IX–treated mutant mice.
Bars represent the median of each group. Error bars represent the interquartile ranges (IQRs): CAGG-CreERþ/;Wt1f/f versus GSI-IX–treated CAGG-
CreERþ/;Wt1f/f mice: 35,836 (IQR: 21,304, 46,371) versus 6657 (IQR: 1337, 10,565), *P ¼ 0.02, Mann-Whitney U test. (g) Western blot analysis
demonstrates albumin in urine samples of vehicle-treated versus GSI-IX–treated mutant mice (molecular weight of albumin: 66.5 kDa). To
optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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podocyte apoptosis, dedifferentiation, and both diffuse
mesangial sclerosis and FSGS phenotypes,27,28 which are also
associated with mutations in WT1.5,7 Following Wt1 deletion
in this model, we show upregulation of several Notch com-
ponents, including Notch1 and its transcriptional target gene,
Nrarp,35 as well as Notch bHLH transcription factors. The
ﬁnding of increased Jagged1 and Pofut1 protein in primary
mutant podocytes at disease induction suggested a ligand-
dependent mechanism of podocyte Notch activation at dis-
ease manifestation. Furthermore, induction of HES1 expres-
sion in transgenic Nphs2;rtTA primary podocytes led to
increased Snail and Slug expression, suggesting that Notch is
activating genes promoting EMT in podocytes. Notch inhi-
bition using gamma secretase inhibitors, on the D4 and D5
following tamoxifen administration, led to a reduction in the
severity of glomerulosclerosis and albuminuria. We propose a
model in which loss of Wt1 in mature podocytes induces
podocyte apoptosis and EMT, which could be mediated via
activation of Notch. These ﬁndings are consistent with pre-
vious reports demonstrating podocyte Notch activation in
chemically induced models of glomerulosclerosis and in hu-
man biopsies of glomerular disease.28,36–38 Increased podo-
cyte Hes1, Hes3, Hes5 and Hey1, Hey2, and HeyL have been
found in streptozotocin- and puromycin aminonucleoside–
induced glomerulosclerosis.28 Podocyte apoptosis has been
shown to play an instigating role in the pathogenesis of FSGS,
and Notch activation in mature podocytes induces
apoptosis.28,30 Conditional activation of the intracellular
domain of Notch1 in mature podocytes is associated with
positive TUNEL staining and upregulation of podocyte Trp53
and Apaf1. Piﬁthrin-a inhibits apoptosis in podocytes trans-
duced with the Notch1 intracellular domain, thereby sug-
gesting that Notch1 induces podocyte apoptosis via the p53
pathway.28 Conditional deletion of podocyte Rbpj in mice
with diabetic nephropathy is associated with reduced podo-
cyte apoptosis providing further support for a role for Notch
in podocyte apoptosis.28 In the current study, we speculate a
role for p53-mediated apoptosis in the pathogenesis of Wt1
glomerulopathy in our model. It would be interesting to
explore whether apoptosis is inhibited with conditional
inactivation of Notch1 in podocytes of adult CAGG-
CreERTMþ/;Wt1f/f transgenic mice. Indeed, conditional
deletion of Notch1, but not Notch2, in podocytes of mice with
diabetic nephropathy abrogates glomerulosclerosis.37
Furthermore, reduced expression of primary podocyte
Snail1 protein and mRNA has been observed in these mice,37
suggesting that podocyte Notch1 activation is associated with
both apoptosis and epithelial mesenchymal transition. Our
study adds to previous studies demonstrating that ectopic
Notch activation in mature podocytes is associated with the
development of glomerular scarring. Conditional inactivation
of Notch1 and its transcriptional targets in both early and late
stages of Wt1 glomerulopathy would further deﬁne the role
and window for Notch activation in disease pathogenesis.
Pharmacological block of Notch signaling has previously
deﬁned a narrow window for Notch in proximal nephron
identity.21–23 However, a recent study suggests that Notch is
required for the formation of all nephron segments and primes
nephron progenitors for differentiation.24 Notch1 and Notch2
are expressed in overlapping patterns in the proximal domain
of the S-shaped body where podocyte precursors reside.23
During terminal podocyte differentiation, Hes/Hey genes are
progressively down-regulated.25,26 Regulation of vertebrate
podocyte differentiation has been proposed to involve a mul-
timeric transcriptional network involving Wt1, FoxC1/C2, and
Rbpj.34,39 FOX transcription factor binding motifs have been
found in a large proportion of WT1-bound regions supporting
coordinated action of these transcription factors in regulating
podocyte-speciﬁc genes.17,18 Double knockdown of either
wt1a/rbpj or wt1a/foxc1a in zebraﬁsh caused a reduction in
podocyte number in contrast to a single knockdown of any of
the 3 genes, supporting a genetic interaction between these
transcription factors in regulation of podocyte speciﬁcation.34
Co-immunoprecipitation studies revealed putative in-
teractions amongWt1, Rbpj, and FoxC2 proteins, and together,
combinations of Wt1, FoxC1/2, and NICD can synergistically
induce Hey1 expression.34 In Xenopus, knockdown of xWT1
decreased the early glomus-speciﬁc expression of XHRT1, the
Hey1 orthologue, but did not perturb its late expression in the
pronephros anlagen, suggesting that xWT1 mediates expres-
sion of XHRT1 early in glomerulogenesis.40HeyL expression in
pretubular aggregates is also regulated by Wt1 during murine
metanephric development and studies of Wt1 target genes in
embryonic mouse kidney tissue revealed that Wt1 can bind to
the HeyL promoter.41 These studies support a role for modu-
lation of Notch transcriptional targets by Wt1 and FoxC1/2
during nephrogenesis.
After the proximal nephron forms, podocytes function
normally in the absence of Notch.25,26 FollowingWt1 deletion
in mature podocytes, we ﬁnd upregulation of Notch pathway
components,Notch1,Nrarp,Hey1, Hey2, HeyL,Hes1,Hes3, and
Hes5. These ﬁndings are consistent with previous studies where
Wt1 and Foxc1a can inhibit the ability of NICD1 to activate a
synthetic Notch reporter driven by Rbpj sites34 and suggest a
model where Wt1 and FoxC1/2 have antagonistic effects on
Notch signaling in the mature podocyte. Our study also
demonstrated that loss of Wt1 in mature podocytes
is associated with a reduction of FoxC2 expression and
upregulation of Notch pathway components coincident with
onset of glomerulosclerosis and albuminuria.We speculate that
FoxC2 could repress expression of Hey2 and other Notch
bHLH genes in mature podocytes, based on our observation of
increasedHey2 transcript in mutant podocytes at a point when
FoxC2 is down-regulated. This would be consistent with a
previous report showing thatHey2 is a transcriptional target of
FoxC2 in endothelial cells.42 Restoration of FoxC2 levels in
adult CAGG-CreERTMþ/;Wt1f/f transgenic mice may be suf-
ﬁcient to restore podocyte-speciﬁc gene expression following
injury, perhaps via repression of Notch bHLH gene expression.
An alternative mechanism of podocyte Notch activation in
Wt1-mediated injury could also be mediated via activation of
Hippo signaling. Kann et al.18 identiﬁed podocyte-speciﬁc
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enrichment for TEAD transcription factor motifs (effectors of
Hippo signaling) in the vicinity of WT1 chromatin immu-
noprecipitation sequencing peaks. Notch ligands are tran-
scriptional targets of Hippo signaling,43 and it is possible that
loss of Wt1 expression in mature podocytes mediates Notch
activation via regulation of Hippo components.
Our observation of increased Pofut1 in mutant podocytes
supports activation of Notch in CAGG-CreERTMþ/;Wt1f/f
transgenic mice. Notch activation relies on O-linked glyco-
sylation of the extracellular domain of Notch receptors and
ligands that inﬂuence receptor sensitivity to ligand stimula-
tion.24 Pofut1 is an O-fucosyltransferase 1 enzyme that
mediates fucosylation of the extracellular domain of the
Notch protein and has recently been shown to play an
important role in the regulation of cell surface expression of
Notch1.33 We also found increased Mfng, a b3-N-acetylglu-
cosaminyltransferase that mediates glycosylation of the
Notch extracellular domain in mutant podocytes.31,32 In most
contexts, Fringe-mediated glycosylation of Notch1 renders it
more sensitive to Dll1-mediated activation.32 We have found
evidence for Jagged1 expression in CAGG-CreERTMþ/;Wt1f/f
transgenic mice and in human biopsies of WT1-mutated
glomerulosclerosis. It will be of interest to study the conse-
quences of Mfng deletion in CAGG-CreERTMþ/;Wt1f/f mice
on disease manifestation.
In the early stages of disease, we observed Jagged1
expression in podocytes and parietal epithelium of mutant
glomeruli. This observation is consistent with previous
reports for a role for Jagged1 in glomerulosclerosis.28,36 In
contrast, we did not observe any quantitative difference in
Delta1 protein expression in primary mutant podocytes
compared with controls in the early stages of disease. Both
Delta1 and Jagged1 share overlapping expression patterns
within the middle segment of the S-shaped body during
kidney development.23 Combined loss of both ligands in Six2-
Cre;Dll1f/f;Jag1f/f transgenic mice results in a severe reduction
in numbers of proximal tubules and glomeruli, thereby sup-
porting a role for ligand-mediated Notch activation in
deﬁning proximal nephron identity.23 Replacement of one
Jag1 allele in the Dll1-null background can rescue some WT1-
positive podocytes, suggesting that an important role for Jag1
in podocyte fate induction.23 In the context of podocyte
injury, Niranjan et al.28 reported that TGF-b1 mediated
treatment of podocytes resulted in Jagged1 upregulation.
Future studies will be directed at examining the effects of
conditional deletion of Jagged1 in adult CAGG-
CreERTMþ/;Wt1f/f mice on disease manifestation.
In summary, we identify podocyte apoptosis as an early
event in the pathogenesis of glomerulosclerosis mediated by
loss of Wt1 function in mature podocytes. At disease onset,
we ﬁnd induction of podocyte EMT gene expression and
upregulation of several Notch pathway components. Induc-
tion of podocyte HES1 expression is associated with increased
Snail and Slug expression, suggesting that HES1 regulates
podocyte EMT. Early pharmacological blockade of Notch
signaling leads to a reduction in the severity of
glomerulosclerosis and albuminuria. We speculate that acti-
vation of Notch is mediated by repression of FoxC2. Given the
recent advances in our understanding of the complex bio-
logical roles of WT1, transgenic mice carrying point muta-
tions relevant to human disease will provide invaluable tools
to investigate the transcriptional networks and post-
transcriptional mechanisms underlying WT1-related
glomerulosclerosis.
MATERIALS AND METHODS
Mouse strains
Wt1 deletion in adult mice was achieved following generation of
bitransgenic mice by crossing CAGG promoter–driven CreERTM
mice with homozygous Wt1 conditional mice, where the ﬁrst exon of
Wt1 is ﬂanked by LoxP sites.29 Site-speciﬁc recombination between
the LoxP sites of the Wt1 gene results in a ubiquitous Wt1 null allele.
Successful Wt1 deletion was demonstrated by recombination PCR
and the depletion of Wt1 expression in podocytes (Supplementary
Figure S1). Mice were maintained on a mixed genetic background
consisting of C57BL/6J and CD1. However, for comparison of
phenotypes such as proteinuria, littermates were used.
Cre recombinase was induced by i.p. administration of tamoxifen
(1 mg/40 g body weight for 3 days; Sigma Aldrich) to 5-week-old
mice. All animal work was carried out under the permission of li-
cense. Mice were housed and bred in animal facilities at the Western
Labs, UCL Great Ormond Street Institute of Child Health. Mice were
killed at D4, D5, D6, D8, and D12 PI of tamoxifen. Bilateral ne-
phrectomies were performed under sterile conditions.
Nphs2;rtTA transgenic mice expressing the tetracycline trans-
activator speciﬁcally in podocytes were used for primary podocyte
cultures and Hes1 overexpression experiments.44
Phenotype analysis
Urinary albumin and creatinine were determined using the mouse
albumin enzyme-linked immunosorbent quantitation set (E90-134;
Bethyl Laboratories) and creatinine assay (KGE005; R&D Systems)
kits, respectively.
Western blot detection of albuminuria was determined following
loading 4 microliters of urine samples (albumin antibody [E90-134;
Bethyl Laboratories] 1:1000 dilution). Kidneys were ﬁxed in in 4%
formaldehyde in phosphate-buffered saline (PBS) and parafﬁn-
embedded kidney sections were stained with PAS.
Primary glomerular harvest and podocyte culture
Fresh kidney cortices were dissected into ice-cold Hanks balance salt
solution (24020-133; Gibco/Invitrogen, Thermo Fisher Scientiﬁc),
decapsulated, and minced. After rinsing thoroughly with fresh Hanks
balance salt solution, the pieces were pushed through a 100-mm cell
strainer (Falcon 352360; BD Biosciences) into a chilled beaker.
Hanks balance salt solution was added to a total of 6 ml, and this was
divided between 2 chilled 15-ml Falcon tubes. Then 2.2 ml of Percoll
(17-0891-02; Amersham) was added to each tube. The samples were
spun at 400 rpm for 10 minutes at 4oC to separate glomeruli across
the Percoll gradient.45 The presence of glomeruli in the top of the
gradient was veriﬁed microscopically. The top 1 to 2 ml were
removed and passed again through a 100-mm cell strainer to catch
any large tubule fragments. The ﬁltrate was then passed through a
40-mm cell strainer (Falcon 352340, BD Biosciences) to trap the
glomeruli.
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For podocyte culture, harvested glomeruli were placed onto
culture dishes coated with 0.1 mg/ml rat tail collagen type I as
previously described. Culture medium from D1 to D3 was RPMI
1640 medium containing 15% fetal bovine serum (FBS) (Atlanta
Biologicals), penicillin streptomycin, and amphotericin B. On D3 of
culture, unattached glomeruli were washed away and medium was
changed to 10% FBS. Podocytes were examined on D6 of culture
after harvest.
Immunoﬂuorescence studies
Tissues were ﬁxed and embedded in parafﬁn or O.C.T. Compound
(Sakura Finetek) as previously described.27 For double and triple
immunoﬂuorescence labeling, formalin-ﬁxed sections were depar-
aﬁnized according to previously published protocols.27 Microwave
antigen retrieval was carried out in citrate buffer in 4 5-minute
cycles at medium-high setting (NN-S758WC, 950W maximum
output; Panasonic) following by a 20-minute cooling period at room
temperature (RT). Blocking was performed in Universal Blocking
Reagent (DAKO). O.C.T. Compound (Sakura) embedded cry-
osections were permeabilized in 0.5% Triton X-100 for 5 minutes,
followed by 2 5-minute PBS washes. They were then incubated in
blocking buffer (10% goat serum, 1% BSA, 0.1% Triton X-100) for
1 hour at RT. Sections were probed with antibodies diluted in
blocking reagent and incubated at 4C overnight. The following day,
sections were washed in PBS and incubated with Alexa Fluor
(Molecular Probes, Invitrogen, Thermo Fisher Scientiﬁc)–conju-
gated secondary antibodies for 1 hour at RT. Slides were mounted
using VECTASHIELD (Vector Laboratories) and nuclei were stained
with DAPI. Confocal imaging was performed using a Zeiss LSM-710
system with an upright DM6000 compound microscope (Leica
Microsystems) and images were processed with Zen software suite
(Zen Software). Z stacks were acquired at 0.5-mm intervals and
converted to single planes by maximum projection with FiJi
software.
Apoptosis studies
TUNEL assay. Cells were seeded on Matrigel (356234; BD Bio-
sciences, San Jose, CA) coated 8-well chamber slides. The following
day, the cells were ﬁxed in 4% paraformaldehyde for 15 minutes and
washed in PBS twice for 5 minutes each time at RT. Cells were then
permeabilized with 0.2% Triton X-100 in PBS for 5 minutes, then
washed in PBS for 5minutes at RT. Then 100 ml of Equilibration buffer
from the DeadEnd Fluorometric TUNEL kit (CAT.G3250; Promega)
was added to the cells for 5 to 10 minutes at RT. Following Equili-
bration buffer, 50 ml rTdT incubation buffer (45 ml Equilibration
buffer þ 5 ml Nucleotide mix þ 1 ml rTdT enzyme) was added to the
cells; to ensure even distribution of the buffer, the slides were covered
with plastic cover slips and incubated at 37C for 1 hour. Plastic
coverslips were removed by immersing the slides 2x SSC for 15 mi-
nutes at RT. Slides were then washed 3 times for 5 minutes each with
PBS at RT. Sections were mounted with VECTASHIELD plus DAPI
mountingmedium (H-1200; Vector Laboratories). Slides were imaged
on a Zeiss ﬂuorescent microscope.
Cleaved Caspase-3/7 staining. Collagen-coated gas-permeable
bottom plates (Corning, Corning, NY) were used to culture
glomeruli for all apoptosis assays. Glomeruli were harvested from
mice 6 days following tamoxifen induction. Following 6 days of
glomerular harvest, unattached glomeruli were washed away with
Dulbecco PBS and the medium was replaced with Roswell Park
Memorial Institute with 0.2% FBS. After 18 hours, CellEvent
Caspase-3/7 Green (Life Technologies, Thermo Fisher Scientiﬁc) to
measure apoptosis were added to each plate per the manufacturers’
instructions. Sections were counterstained with DAPI.
Annexin V staining. Following tissue dissociation, the samples
were spun down at 320g for 5 minutes and washed with the Annexin
V Binding Buffer (88-8103-74; Thermo Fisher Scientiﬁc). The cells
were then stained with Annexin V-PE-Cy7 for 30 minutes on ice, in
the dark. After the incubation period, the samples were again washed
and resuspended in the Annexin V Binding Buffer. Just prior to
sample acquisition, each sample was stained with Sytox Blue at a
ﬁnal concentration of 0.3 mmol/l (S34857; Thermo Fisher Scienti-
ﬁc). The samples were acquired using a 5-laser BD LSRFortessa X-20
Analyser, equipped with 355 nm (ultraviolet), 405 nm (violet), 488
nm (blue), 561 nm (yellow), and 640 nm (red) lasers. Prior to cell
acquisition, the cells were ﬁltered through a 35-mm cell strainer to
prevent cellular aggregation during sample acquisition.
Antibodies and reagents
The following antibodies were used: cleaved Notch1 (Val1744, rab-
bit; Cell Signaling Technologies, Danvers, MA) 1:100 immunohis-
tochemistry, 1:50 immunoﬂuorescence; Notch1 (D1E11; Cell
Signaling) 1:1,000 Western blot; cleaved Notch2 (cleaved-Ala1734,
rabbit; Sigma-Aldrich) 1:150 immunohistochemistry; cleaved
Notch2 (07-1234, rabbit; Millipore) 1:200 immunoﬂuorescence,
1:1,000 Western blot; Jagged 1(C-20, goat; Santa Cruz Biotech-
nology), 1:100 immunoﬂuorescence; Podoplanin (811, hamster;
Novus Biologicals, Littleton, CO), 1:100 immunoﬂuorescence; CD31
(0026, rat; BD Pharmingen, BD Biosciences), 1:100; Hes1 (rabbit,
kind gift from Professor Ryoichiro Kageyama, University of Kyoto,
Japan), 1:1000; Synaptopodin (G1D4, mouse; PROGEN Biotechnik,
Heidelberg, Germany); Podocin (P0372; Sigma Aldrich) 1;100; bio-
tinylated Lotus tetragonolobus lectin, LTL (B-1325; Vector Labora-
tories) 1:100; and cleaved Caspase-3 (Asp175, rabbit; Cell Signaling
Technologies), 1:400 immunoﬂuorescence. Alexa Fluor–conjugated
secondaries 488, 595, and 647 (Molecular Probes, Invitrogen,
Thermo Fisher Scientiﬁc).
GSI-IX (N-[N-(3,5-diﬂuorophen-acetyl-L-alanyl)]-S-phenylglycine
t-butyl ester, or DAPT) were purchased from Sigma Aldrich (D5942)
and administered by i.p. injection (100 mg GSI-IX/40 g body weight) on
the evening of day D4 PI of tamoxifen to CAGG-CreERTM þ/;Wt1f/f
transgenic mice. Vehicle treatment with dimethyl sulfoxide (W387520;
Sigma Aldrich) administered by i.p. injection (100 mg GSI-IX/40 g
body weight) on the evening of D4 PI of tamoxifen to CAGG-
CreERTM þ/;Wt1f/f transgenic mice were used as controls. For late
treatments, CAGG-CreERTMþ/;Wt1f/f mutants were treated by i.p.
injectionwith the gamma secretase inhibitorGSI-IXDAPT (100mg/40 g
mouse body weight) on the evening of D7 PI of tamoxifen and treated
againwithDAPT the nextmorning (16 hours later). Urinewas collected
at least 8 hours following the second DAPT treatment and mice were
then sacriﬁced. Following nephrectomy, light microscopic examination
of PAS-stained specimens were scored for severity of glomerulo-
sclerosis. Comparison was made between GSI-DAPT and vehicle-
treated CAGG-CreERTMþ/;Wt1f/f transgenic mice.
Transfection experiments
Primary transgenic murine Nphs2;rtTA podocytes were transfected
with TetOHes1 plasmid (6154; Addgene)46 or control-GFP-only
plasmid with Lipofectamine 3000 kit (L3000001; Thermo Fischer
Scientiﬁc). Cells were transfected at 70% conﬂuency. Following 24
hours, both TetOHes1 and control-plasmid transfected cells were
treated with doxycycline (2 and 4 mg/ml) for 72 and 96 hours’
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duration. RNA extraction was undertaken according to manufac-
turer’s instructions using the Qiagen microRNA extraction kit.
Protein was extracted as previously described.47
shRNA experiments
For MFng and Rbpsuh gene knockdown, the Thermo Scientiﬁc Open
Biosystems pGIPZ MFng (V3LMM_20363), and Rbpsuh
(V3LMM_437682) and nonsilencing control vectors (RHS4346) were
used. Primary podocytes from D6 PI CAGG-CreERTMþ/;Wt1f/f
transgenic mice were cultured in Roswell Park Memorial Institute
medium in 10% FBS and 1% insulin, transferrin, and selenium. Next,
1  105 cells were seeded per well in 6-well dishes (plastic bottom) in
duplicates, 24 hours prior to being transfected with 4 mg of MFng and
Rbpsuh short hairpin RNA (shRNA) and 4 mg nonsilencing control
vector. One plate was harvested to determine knockdown efﬁciency by
quantitative real-time (qRT)-PCR 48 hours following transfection.
RNA extraction and qRT-PCR
Following primary podocyte derivation, total RNAwas isolated using
the RNeasy Micro Kit (Qiagen). cDNA was synthesized by reverse
transcription using a high-capacity RNA-to-cDNA kit (4387406; Life
Technologies, Thermo Fisher Scientiﬁc), qRT-PCR was performed
with 250 ng cDNA on a Bio-Rad qPCR machine (CFX96 touch real-
time PCR detection system; Hercules, CA) using SYBR Green PCR
Master Mix (Applied Biosystems) and 0.45 mg of the oligonucleotides
(Sigma Aldrich) outlined in Supplementary Tables S1 and S2. For
each gene, the reaction was run in duplicate for between 6 and 10
samples, and for each primer pair, a no-template control was
included. The data were normalized to Gapdh gene levels within each
sample and analyzed using the DDCt method.48
Western blotting
Protein was isolated using radioimmunoprecipitation assay buffer
supplemented with phosphatase and protease inhibitors. Lysis was
completed by shearing through a 26-gauge syringe needle. Samples
were denatured with 10% b-mercaptoethanol (Sigma Aldrich) in 4X
Laemmli sample buffer at 95C for 10 minutes. Primary podocytes
were run on 4% to 15% sodium dodecylsulfate–polyacrylamide gel
electrophoresis gradient gels (Bio-Rad Laboratories). Immortalized
podocytes were run on 10% sodium dodecylsulfate–polyacrylamide
gel electrophoresis gels. All gels were transferred onto polyvinylidene
ﬂuoride and blocked in 5% nonfat milk in PBS before being probed
with primary antibodies and secondary antibodies. Blots were devel-
oped with Pierce ECL Western Blotting Substrate (Thermo Fisher
Scientiﬁc).
Statistics
Statistical analyses were performed in GraphPad Prism V.7 (GraphPad
Software). For each analysis, we examined at least 6 to 10 independent
samples per experimental group; for qRT-PCR analysis, the average of
duplicate reactions was used as the value of that sample. Where data is
normally distributed, results are expressed as mean  SD or SEM
relative to the speciﬁed controls. Where data is not normally distrib-
uted, results are reported as medians with respective interquartile
ranges. For all statistical analyses, we used a 2-tailed, unpaired Student
t-test or Mann-Whitney U test to analyze the difference between 2
groups. The Bonferroni correction was used when more >2 groups
were present. Values were regarded signiﬁcant if <0.05; all error bars
represent SDs.
Study approval
Animal experiments were conducted with ethical approval from the
Animal Welfare and Ethical Review Body of the University College of
London, Great Ormond Street Institute of Child Health and carried
out under United Kingdom Home Ofﬁce license 70/7892. Approval
for research on human tissue was obtained from the NHS National
Research Ethics Service (NRES) Committee, North-East York, UK.
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SUPPLEMENTARY MATERIAL
Figure S1. Wilms’ tumor 1 (Wt1) is deleted at day (D) 4, D5, and D12
postinduction (PI) of tamoxifen. (A–C0) Representative micrographs of
WT1 protein expression in glomeruli following immunoﬂuorescence
labeling of CreTM/;Wt1f/f control mouse kidney tissue sections
versus Cre TMþ/;Wt1f/f mutants. Bars ¼ 50 mm. Images were
counterstained with 40,6-diamidino-2-phenylindole (DAPI). (A,A0) D4
PI controls show WT1 protein expression as indicated by red arrows
(A) in comparison to mutants, where WT1 protein expression is
reduced (A0). (D) DNA expression of Wt1 PI of tamoxifen following
polymerase chain reaction analysis. Recombination is present in the
mutants, but no recombination is seen in controls. (B,B0) D5 PI
micrographs highlighting WT1 protein expression in controls, as
indicated by arrows (B), versus mutants, where no WT1 protein is
observed (B0). (E) Polymerase chain reaction analysis of Wt1 geno-
typing PI of tamoxifen in mutants versus controls. Wt1 amplicon is
reduced and recombination is shown in the mutant. (C,C0) Repre-
sentative micrographs of glomeruli following immunoﬂuorescent
labeling of podocytes with WT1 in D12 PI sections. WT1 protein is
present in controls, as indicated by the red arrows (C), versus mu-
tants, where WT1 is absent (C0). (F) Quantitative real-time polymerase
chain reaction graph highlighting mRNA expression of Wt1 relative to
Gapdh showing a reduction of Wt1 in the mutant versus control.
Figure S2. Wilms’ tumor 1 (WT1) is expressed in Cre(þ);Wt1f/þ
transgenic mice postinduction (PI) of tamoxifen. (A-C) Representative
micrographs of glomeruli following immunoﬂuorescent labeling
of podocytes with anti-WT1 antibody in day (D) 4, D8, and D12
Cre TMþ/;WT1f/þ heterozygotes PI. Bars ¼ 50 mm. (A) At D4 PI, WT1
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protein is expressed in Cre TMþ/;Wt1f/þ glomeruli following tamoxifen
induction, as indicated by arrows. (B) WT1 protein expression is present
at D8 PI in the heterozygotes, as seen by the arrows. (C) By D12 PI, WT1
protein is still present in the heterozygotes. (A0,B0) Hematoxylin and
eosin–stained sections of glomeruli at D4, D8, and D12 PI. Bar¼ 25 mm.
(A0)Mice exhibit healthy glomeruli with nohistological abnormalities at
D4 PI. (B0) At D8 PI, no hyaline presence or glomerulosclerosis and
glomeruli are intact. (C0) No histological abnormalities in the glomeruli
by D12 PI with no hyalinematerial in either the glomeruli or tubules. (D)
Quantitative graph showing mean urine albumin-creatinine ratio (mg/
mg) at D4 PI controls versus heterozygotes versus mutants (n ¼ 14 vs.
n¼ 8 vs. n¼ 10): 104.4 25.7 versus 174.9 27.0 versus 563.5 443.9,
P ¼ 0.21, Student t-test. (E) Quantitative graph showing mean urine
albumin-creatinine ratio (mg/mg) at D12 PI controls versus heterozy-
gotes versus mutants (n ¼ 8 versus n ¼ 3 versus n ¼ 7): 76.8  13.9
versus 223.5  93.8 versus 9469  4279, P ¼ 0.21, Student t-test. (F)
Western blot analysis of urine samples of CreTM/;Wt1f/f, CreTMþ/
;Wt1f/þ, and CreTMþ/;Wt1f/f at D8 PI probed with anti-albumin.
Albuminuria is detected in the mutant and absent in both controls
(molecular weight of albumin: 66.5 kDa).
Figure S3. Induction and severity of glomerulosclerosis at day (D) 4,
D5, D6, and D12 postinduction (PI). (A-D) Quantitative graphs of
proportion of glomeruli per genotype revealing extent of
glomerulosclerosis (score 0: <25% glomerulus sclerosed; score 1:
25%–50% sclerosis; score 2: 50%–75% sclerosis; score 3: >75%
sclerosis). (A) At D4 PI, none of the transgenic mice exhibited global
glomerulosclerosis (>75% sclerosis, score 3). A signiﬁcant proportion
of mutants exhibited segmental glomerulosclerosis (<50%, score 1)
compared with controls and heterozygotes: D4 PI: CreERþ/;Wt1f/þ
(heterozygotes) (n ¼ 90 glomeruli, n ¼ 3 mice) versus CreER/;Wt1f/f
(controls) versus CreERþ/;Wt1f/f (n ¼ 90 glomeruli, n ¼ 3 mice)
(mutants) transgenic mice. Score 0: 94% (interquartile range [IQR]: 86,
96) versus 81% (IQR: 73, 97) versus 80% (IQR: 77, 90), P ¼ 0.06; score 1:
6% (IQR: 4, 14) versus 16% (IQR: 3, 24) versus 23% (IQR: 20, 26). Bars
represent the median percentage of each score per genotype. Error
bars represent the IQR, *P < 0.05, Mann-Whitney U test. (B). At D5 PI,
a signiﬁcant proportion of mutant glomeruli with more extensive
segmental sclerosis were observed compared with controls and
heterozygotes: D5 PI: CreERþ/;Wt1f/þ (n ¼ 60 glomeruli) versus
CreER/;Wt1f/f (n ¼ 90 glomeruli) versus CreERþ/;Wt1f/f (n ¼ 90
glomeruli): score 0: 85  2% versus 78 8.5% versus 3  3%,****P <
0.0001, Student t-test; score 1: 11.5  5.5% versus 20  7.6% versus
19  3.1%; P ¼ 0.5 (not signiﬁcant); score 2: 3  3% versus 21%
versus 32  14.5%, *P < 0.05; score 3: 0% versus 0% versus 20 
12.2%, *P < 0.05, Student t-test. Bars represent the mean percentage
of each score per genotype. Error bars represent the SEM. ****P <
0.0001, *P < 0.05, Student t-test. (C) At D6 PI, more extensive glo-
merulosclerosis (40% with score 3 vs. 1% heterozygotes and 0% for
controls) was evident in mutants compared with controls. (D) By D12
PI, the majority of glomeruli exhibited >75% glomerulosclerosis: D12
PI CreERþ/;Wt1f/þ versus CreER/;Wt1f/f (n ¼ 60 glomeruli) versus
CreERþ/ ;Wt1f/f (n ¼ 61 glomeruli) transgenic mice. Score 0: 88.5%
(IQR: 87, 90) versus 78% (IQR: 76, 80) versus 0% (IQR: 0, 0), ***P <
0.001, 2-way analysis of variance (ANOVA); score 1: 11.5% (IQR: 10, 13)
versus 22% (IQR:0, 24) versus 0% (IQR: 0, 3), ***P < 0.001, 2-way
ANOVA; score 2: 0% versus 0% versus 21% (IQR: 20, 22), ***P < 0.001,
2-way ANOVA; score 3: 0% versus 0% versus 79% (IQR: 78, 80), ***P <
0.001, 2-way ANOVA.
Figure S4. Podocyte foot process effacement at day (D) 4
postinduction (PI) in CAGG-CreERTM+/-;Wt1f/f transgenic mice. (A,B)
Representative electron micrographs demonstrating focal foot
process effacement in mutant mice (B) as early as D4 PI compared
with control mice (A).
Figure S5. Induction of vascular smooth muscle actin expression in
CreERTMþ/;Wt1f/f transgenic mice. (A-F) Shown are micrographs of
glomeruli following double immunoﬂuorescence labeling of
transgenic mouse kidney tissue sections with anti-a smooth muscle
actin (SMA) (Alexa Fluor 488–conjugated secondary antibody) and
Lotus tetragonolobus lectin (LTL) (Alexa Fluor 594–conjugated
secondary antibody) at day (D) 12 PI. Images were counterstained
with 40,6-diamidino-2-phenylindole. Bars ¼ 50 mm. (A–F) Expansion
of a-SMA expression is noted in tubulointerstitial compartment in
mutants (D) compared with controls (A). (C,F) High-power views of
tubulointerstitium. a-SMA expression (green arrows) is induced in
peritubular cells (red arrows, tubules) in CreERTMþ/;Wt1f/f transgenic
mice (F) that is not seen in control CreERTM/;Wt1f/f transgenic mice
(C). Bars ¼ 50 mm. (G–L) High-power views of proximal nephron and
glomeruli. Vascular SMA expression (green arrows) is observed in
CreERTMþ/;Wt1f/f transgenic mice (L) in clusters of glomerular cells
within Bowman’s capsule, intraglomerular tuft region, and the pari-
etal epithelium in CreERTMþ/;Wt1f/f and not in control CreERTM/
;Wt1f/f transgenic mice (G). Bars ¼ 50 mm.
Figure S6. Terminal deoxynucleotidyltransferase–mediated
20-deoxyuridine 50-triphosphate nick end-labeling (TUNEL)-positive
cells in glomeruli of CAGG-CreERTMþ/;Wt1f/f transgenic mice. (A,A0)
TUNEL-positive and 40,6-diamidino-2-phenylindole (DAPI)-positive
cells (inset) in mutant mice (A0) at day 5 postinduction compared with
controls (A). (B) Quantitative graph showing increased proportion of
median number of TUNEL-positive podocytes. Bars represent the
median of each group. Error bars represent interquartile ranges,
*P < 0.0001, Mann-Whitney U test. See also Figure 2c for TUNEL-
positive primary podocytes of mutant versus control mice.
Figure S7. Cleaved Caspase 3/7 is induced in primary CAGG-
CreERTMþ/;Wt1f/f transgenic podocytes. (A,B) Representative micro-
graphs following immunoﬂuorescent labeling with anticleaved Cas-
pase-3 & 7 (Alexa 488–conjugated secondary antibody, green arrows)
of primary podocytes isolated at D6 P.I. from control (A) and mutant
(B) mice. (C) Quantitative graph showing the proportion of median
number of cleaved Caspase-3/7–positive podocytes in mutants and
controls. Bars represent the median of each group. Error bars repre-
sent the interquartile ranges. Median percentage of DAPI-positive,
cleaved Caspase 3/7–positive podocytes in controls (n ¼ 9) versus
mutants (n ¼ 15): 0% (IQR: 0, 6.56) versus 6.8% (IQR: 0, 16.7), P ¼ 0.19
(not signiﬁcant), Mann-Whitney U test.
Figure S8. Podocyte apoptosis is increased in CAGG-CreERTMþ/;Wt1f/f
transgenic mouse podocytes at day 8 postinduction (A-C). (A,B)
Representative ﬂow cytometry results for primary podocytes from day
8 postinduction CAGG-CreERTM /;Wt1f/f control and CAGG-CreERTM þ/
;Wt1f/f mutant transgenic mice. The abscissa and ordinate represent
the ﬂuorescence intensity of Annexin V Cy7 and Sytox blue,
respectively. (C) Quantitative analysis of podocyte cell death. Bars
represent the mean percentages  SEM of Annexin V–positive/Sytox
blue–positive (late apoptotic/necrotic) podocytes. CAGG-CreERTM /
;Wt1f/f controls (n ¼ 2) versus CAGG-CreERTM þ/;Wt1f/f mutants (n ¼
2): 2.1  0.5% versus 4.0  0.7%, P ¼ 0.16 (not signiﬁcant). Analyzed
by Student t-test. (D) Annexin V/Sytox–negative cells (early
apoptosis); 1.6  0.56% versus 5.0  1.3%, P ¼ 0.13. Analyzed by
Student t-test.
Figure S9. Terminal deoxynucleotidyltransferase–mediated
20-deoxyuridine 50-triphosphate nick end-labeling (TUNEL)-positive
cells in glomeruli of CAGG-CreERTMþ/;Wt1f/f transgenic mice at day
(D) 12 postinduction (PI). (A-D) Shown are micrographs of glomeruli
of transgenic mouse kidney tissue sections labeled with TUNEL (green
arrows) and counterstained with 40,6-diamidino-2-phenylindole
(DAPI) at D12 PI. Bars ¼ 25 mm. (A) CAGG-CreERTM/;Wt1f/f controls
display no TUNEL-positive cells in the glomerulus. (B-D)
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Representative micrographs for D12 PI CAGG-CreERTM/;Wt1f/f mu-
tants exhibiting TUNEL-DAPI-positive cells in the glomeruli. See also
Figure 2c for TUNEL-positive primary podocytes of mutant versus
control mice.
Figure S10. Relative transcript levels of the Notch pathway
components in primary podocytes of CreERTM/;Wt1f/f versus
CreERTMþ/;Wt1f/f at day (D) 4 postinduction (PI) and D5 PI. (A) Notch
pathway transcripts in D4 PI CreERTMþ/;Wt1f/f mutants compared
with CreERTM/;Wt1f/f controls. Mean mRNA transcripts relative to
Gapdh ( SEM, CreERTM/;Wt1f/f versus CreERTMþ/;Wt1f/f); Notch1:
1.1  0.2 versus 0.9  0.2 (P ¼ 0.45); Notch2: 1.3  0.3 versus 2.5  0.8
(P ¼ 0.18); Hes1: 2.8  0.6 versus 3.5  0.4 (P ¼ 0.37); Hes5: 1.1  0.2
versus 2.2  0.9 (P ¼ 0.27); HeyL: 1.4  0.6 versus 8.5  5.4 (P ¼ 0.23);
Mfng: 1.8  0.6 versus 7.8  4.4 (P ¼ 0.16), Student t-test. (B) Notch
pathway transcripts in D5 PI CreERTMþ/;Wt1f/f mutants compared
with CreERTM/;Wt1f/f controls: Notch1: 1.3  0.2 versus 1.2  0.29
(P ¼ 0.88); Notch2: 1.5 0.16 versus 1.9  0.31 (P ¼ 1.47); Hes1: 2.5 
0.4 versus 2.2  0.5 (P ¼ 0.73); Hes3: 1.2  0.1 versus 0.88  0.09 (P ¼
0.05); Hes5: 1.5  0.6 versus 1.3  0.25 (P ¼ 0.8); HeyL: 2.5  0.97
versus 2.6  0.8 (P ¼ 0.9); Mfng: 1.8  0.6 versus 7.8  4.4 (P ¼ 0.16),
Student t-test.
Figure S11. Hes1 protein expression is increased following
doxycycline treatment in transduced Nphs2;rtTA podocytes.
Representative image of a Western blot analysis of protein lysates
from doxycycline-treated primary Nphs2;rtTA podocytes trans-
duced with TetOHes1 and green ﬂuorescent protein plasmids.
Hes1 protein expression was increased following an increased
dose of doxycycline in the TetOHes1 transduced podocytes and
no Hes1 protein expression was observed in green ﬂuorescent
protein–transduced Nphs2;rtTA podocyte lysates postdoxycycline
treatment.
Figure S12. Wt1 expression is unchanged in Vehicle versus GSI-IX-
treated CAGG-CreERTMþ/–; Wt1f/f transgenic mice. (A) Shown are
merged micrographs of kidney sections following immunoﬂuorescent
labeling of kidney tissue sections of CAGG-CreERTM–/–; Wt1f/f, CAGG-
CreERTMþ/–; Wt1f/f, vehicle versus GSI-IX-treated CAGG-CreERTMþ/–;
Wt1f/f transgenic mice with Wt1 (Alexa Fluor 594-conjugated
secondary antibody). Scale bars ¼ 50 mm. (B) Relative transcript levels
of Wt1 in primary podocytes of CAGG-CreERTM;Wt1f/f (control),
CAGG-CreERTMþ/;Wt1f/f (mutant), vehicle-treated CAGG-CreERTMþ/
;Wt1f/f, and GSI-IX–treated CAGG-CreERTMþ/;Wt1f/f transgenic mice.
Bars represent the mean, error bars represent the SEM. CAGG-
CreERTM/;Wt1f/f versus CAGG-CreERTMþ/;Wt1f/f: 1.1  0.2 versus 0.4
 0.4, *P ¼ 0.03, Student t-test; CAGG-CreERTM/;Wt1f/f versus
vehicle-treated CAGG-CreERTMþ/;Wt1f/f mice: 1.1  0.2 versus 0.4 
0.2, P ¼ 0.07, Student t-test; vehicle-treated CAGG-CreERTMþ/;Wt1f/f
mice versus GSI-IX–treated CAGG-CreERTMþ/;Wt1f/f transgenic mice:
0.4  0.2 versus 0.4  0.3, P ¼ 0.93, Student t-test. n.s., not signiﬁcant.
Figure S13. Gamma secretase inhibition (GSI-IX) in late Wt1
glomerulopathy does not rescue disease (A-E). (A) Shown are
representative micrographs of hematoxylin and eosin–stained
kidney sections of GSI-IX-treated CAGG-CreERTMþ/;Wt1f/f and
vehicle (dimethylsulfoxide)-treated CAGG-CreERTMþ/;Wt1f/f
mutant mice treated the evening of day (D) 7 postinduction (PI)
(established disease with renal impairment). Vehicle-treated mice
(top panel) exhibit global glomerulosclerosis with hyaline material
in the tubules. Top left image represents a lower-power image of
the glomeruli and tubules, with hyaline material in the tubules
(indicated by white arrows, bar ¼ 50 mm); top right panel shows a
high-power image of the glomerulus with global glomerulo-
sclerosis (indicated by white arrows, bar ¼ 25 mm). Glomeruli of
GSI-IX–treated mice (bottom panel) show the same degree of
glomerulosclerosis as do vehicle-treated mice, with global
glomerulosclerosis. Bottom left image represents a lower-power
image of the glomeruli and tubules, with hyaline-ﬁlled tubules
(indicated by white arrows, bar ¼ 50 mm); bottom right panel
shows a high-power image of the glomerulus, with severe glo-
merulosclerosis (indicated by white arrows, bar ¼ 25 mm). (B)
Shown are merged micrographs of kidney sections following
double immunoﬂuorescence labeling of vehicle- and GSI-IX–
treated CAGG-CreERTMþ/;Wt1f/f kidney tissue sections with a-
smooth muscle actin (SMA) (Alexa Fluor 488–conjugated second-
ary antibody) and anti-Lotus tetragonolobus lectin (LTL) (Alexa
Fluor 594–conjugated secondary antibody). Bars ¼ 50 mm. Top
panel represents lower power image (left) of the tubules and
glomeruli in vehicle-treated mutants, highlighting SMA between
the tubules (green arrows), indicating tubulointerstitial disease;
higher-power (right) shows SMA-positive staining in dilated
capillary loop (green arrow). Bottom panel: low-power image (left)
of the tubules and glomeruli in GSI-treated mutants, showing SMA
in peritubular interstitium (green arrows); higher-power (right)
image highlights the glomerulus with SMA expression within the
glomerular tuft (green arrows). (C) Quantitative graph of glomer-
ulosclerosis index (score 0–3: 0, <25%; 1, 25%–50%; 2, 50%–75%;
3, >75% sclerosis). Vehicle-treated mutants (n ¼ 62 glomeruli, n ¼
2 mice) versus GSI-IX–treated mutants (n ¼ 66 glomeruli, n ¼ 2
mice). Bars represent the mean of each group, error bars represent
the SEMs. Score 0: 0% versus 8.5  8.5%, P ¼ 0.42, Student t-test;
score 1: 9  5% versus 28.5  3.5%, P ¼ 0.09, Student t-test; score
2: 20.5  1.5% versus 28  11%, P ¼ 0.57, Student t-test; score 3:
72.5  8.5% versus 49  9%, P ¼ 0.20, Student t-test. (D) Quan-
titative graph showing mean urine albumin-creatinine ratio in
vehicle-treated (n ¼ 3) versus GSI-IX–treated (n ¼ 1) CAGG-
CreERTMþ/;Wt1f/f transgenic mice. Bars represent the mean, error
bars represent the SEMs. (E) Western blot analysis demonstrates
albuminuria in D8 PI CAGG-CreERTMþ/;Wt1f/f vehicle-treated
CAGG-CreERTMþ/;Wt1f/f and GSI-IX–treated CAGG-CreERTMþ/;
Wt1f/f transgenic mice but not in CAGG-CreERTM/;Wt1f/f control
mice (molecular weight of albumin: 66.5 kDa).
Figure S14. Manic fringe (Mfng) and Rbpsuh short hairpin RNA
(shRNA) knockdown in day (D) 6 postinduction (PI) CAGG-
CreERTM/þ;Wt1f/f podocytes results in repression of Notch basic
helix loop helix (bHLH) targets (A–D). (A) Relative transcript levels
of Rbpsuh (canonical Notch target) in D6 PI primary podocytes of
CAGG-CreERTM/;Wt1f/f controls (n ¼ 7) versus CAGG-CreERTM/
þ;Wt1f/f mutants (n ¼ 10). Bars represent the median level, error
bars represent interquartile range (IQRs). Rbpsuh expression is
increased in D6 PI CAGG-CreERTM/þ;Wt1f/f mutants versus Cre-
negative controls: 0.95 (IQR: 0.79, 1.27) versus 1.45 (IQR: 1.01, 2.09),
P ¼ 0.05, Mann-Whitney U test. (B) Relative transcript levels of
Rbpsuh, Notch bHLH components, Hes1, Hes3, and Hes5, Snail, Slug
(markers of epithelial to mesenchymal transition [EMT]), podocyte-
speciﬁc transcripts Wt1, Nphs1, and Nphs2 and apoptosis compo-
nents Apaf1, Bax, and p53 following 48 hours of Rbpsuh shRNA
knockdown. Bars represent the mean, error bars represent the
SEMs. Scrambled shRNA (Scr) CAGG-CreERTM/þ;Wt1f/f mutants
(n ¼ 2) versus shRNA Rbpsuh-CAGG-CreERTM/þ;Wt1f/f mutants
(n ¼ 2); Rbpsuh: 1.0  0.15 versus 0.6  0.1, P ¼ 0.12; Hes1: 1.0 
0.04 versus 0.6  0.05, *P ¼ 0.02; Hes3: 1.0  0.02 versus 0.7 
0.004, **P ¼ 0.002; Hes5: 1.0  0.27 versus 0.4  0.3, P ¼ 0.24; Wt1:
1.0  0.02 versus 0.8  0.13, P ¼ 0.23; Snail: 1.0  0.21 versus
1.0  0.02, P ¼ 0.92; Slug: 1.0  0.2 versus 0.9  0.04, P ¼ 0.61;
Apaf1: 1.0  0.1 versus 0.71  0.2, P ¼ 0.31; Bax: 1.1  0.35 versus
0.8  0.2, P ¼ 0.60; p53: 1.0  0.0 versus 0.7  0.2, P ¼ 0.27.
Student t-test. (C) Relative transcript levels of Manic fringe in
CAGG-CreERTM/;Wt1f/f controls versus CAGG-CreERTM/þ;Wt1f/f
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mutants at D4, D5, and D6 PI. Bars represent the mean, error bars
represent the SEMs. D4: Mfng: 2.4  1.8 versus 1.1  0.2, P ¼ 0.44;
D5: Mfng: 1.8  0.6 versus 7.8  4.4, P ¼ 0.16; D6: Mfng: 1.9  0.9
versus 5.0  2.4, P ¼ 0.19. Student t-test. (D) Relative transcript
levels of Rbpsuh, Notch bHLH components, Hes1, Hes3, Hes5, Snail,
Slug (markers of EMT), and podocyte-speciﬁc transcript Wt1
following 48 hours of MFng shRNA knockdown. Scrambled shRNA
transfected (Scr) CAGG-CreERTM/þ;Wt1f/f (n ¼ 2) versus Manic
fringe shRNA (shMfng) transfected CAGG-CreERTM/þ;Wt1f/f (n ¼ 2).
Bars represent the mean, error bars represent SEMs. Mfng
expression is reduced following shRNA knockdown. Scr versus
shMFng: 1.3  0.7 versus 0.1  0.01, P ¼ 0.22. Wt1 transcript levels
are equivocal in both groups posttransfection, 1.0  0.1 versus 1.1
 0.5, P ¼ 0.78. Notch components, Hes1, and Hes5 are reduced in
shRNA Mfng podocytes compared with Scr podocytes. Mean
transcript in controls versus shRNA MFng: Hes1: 0.9  0.5 versus 0.5
 0.2, P ¼ 0.58; Hes5: 1.5  1.4 versus 0.2  0.1, P ¼ 0.44. EMT
marker, Snail is reduced: 4.4  2.8 versus 3.2  2.3, P ¼ 0.79; Slug
is similar: 1.1  0.3 versus 1.0  0.1, P ¼ 0.79. Analyzed by Student
t-test.
Table S1. Genomic primers for genotyping.
Table S2. Real-time quantitative polymerase chain reaction primers.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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